Skip to main content
. 2004 Apr 27;90(10):2042–2048. doi: 10.1038/sj.bjc.6601833

Figure 2.

Figure 2

The mean percentage of PB CD3+/CD4+/CD152+ cells (A) and CD3+/CD8+/CD152+ cells (B) before and after ex vivo 24, 48, 72, 96 and 120 h of anti–CD3+rIL-2 stimulation in patients with B-CLL and normal subjects.